BUSINESS
With Current R&D Model Reaching Its Limit, Industry Going Digital to Boost Efficiency: Astellas Chairman
The pharmaceutical industry is working to leverage the advancement of digital technologies and personalized and preemptive medicine to streamline drug development amid snowballing R&D costs, Astellas Pharma Chairman Yoshihiko Hatanaka tells Jiho. “The current business model of the pharmaceutical industry…
To read the full story
BUSINESS
- AGC Biologics Launches Bispecific Antibody CDMO Project in Japan
May 28, 2026
- Bayer Regulatory Chief Hails Japan’s Review System, Flexibility on PI Waivers
May 28, 2026
- Asahi Kasei Licenses ADC Technology from Noguchi Institute
May 28, 2026
- Kissei Files Rigel’s AML Drug Olutasidenib in Japan
May 28, 2026
- Japan OTC Market Falls 2.4% in April amid Weaker Inbound Demand: Intage
May 28, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





